T. Straetemans

发表

TEG011 persistence averts extramedullary tumor growth without exerting off‐target toxicity against healthy tissues in a humanized HLA‐A*24:02 transgenic mice

A. de Bruin, F. Ishikawa, L. Shultz, 2020, Journal of leukocyte biology.

T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies

S. Sleijfer, C. Lamers, R. Debets, 2010, Expert opinion on biological therapy.

Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells

W. Uckert, W. Scheper, R. Oostvogels, 2021, Molecular therapy. Methods & clinical development.

TCRGene Transfer : MAGE-C 2 / HLA-A 2 andMAGE-A 3 / HLA-DP 4 Epitopes as Melanoma-Specific Immune Targets

B. Lambrecht, M. Broertjes, P. Coulie, 2012 .

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets

B. Lambrecht, M. Broertjes, P. Coulie, 2012, Clinical & developmental immunology.

The next step toward GMP-grade production of engineered immune cells

J. Kuball, T. Straetemans, M. D. de Witte, 2016, Oncoimmunology.

γ9δ2T cell diversity and the receptor interface with tumor cells.

A. Heck, D. Olive, K. Lidke, 2020, The Journal of clinical investigation.

γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs.

R. Strong, A. Martens, W. Scheper, 2012, Blood.

Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control

A. de Bruin, W. Scheper, R. Oostvogels, 2021, Frontiers in Immunology.

γδ T-cell receptors derived from breast cancer–infiltrating T lymphocytes mediate antitumor reactivity

Ralf, K. Heise, D. Chudakov, 2020 .

γ9δ2 T-Cell Expansion and Phenotypic Profile Are Reflected in the CDR3δ Repertoire of Healthy Adults

Z. Sebestyén, J. Kuball, D. Beringer, 2022, Frontiers in Immunology.

Uncovering the mode of action of engineered T cells in patient cancer organoids

Annelisa M Cornel, H. Clevers, A. Eggermont, 2022, Nature Biotechnology.

(cid:1) 9 and (cid:2) 2CDR3 domains regulate functional avidity of T cells harboring 2TCRs

R. Strong, A. Martens, W. Scheper, 2012 .

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu

S. Sleijfer, R. Mathijssen, C. Lamers, 2013, Front. Immunol..

Towards clinical TCR gene therapy: tumor models and receptors

T. Straetemans, 2012 .

γδ T-cell Receptors Derived from Breast Cancer–Infiltrating T Lymphocytes Mediate Antitumor Reactivity

K. Heise, R. Küppers, D. Chudakov, 2020, Cancer Immunology Research.

Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer

H. Bönig, I. Slaper-Cortenbach, Z. Sebestyén, 2015, Clinical Cancer Research.

GMP-ready purified engineered immune cells to treat cancer Running title : Purified engineered immune cells

H. Bönig, I. Slaper-Cortenbach, Z. Sebestyén, 2015 .

Successive immunoglobulin and cytokine expression in the small intestine of juvenile chicken.

A. Schots, L. Kruijt, H. Parmentier, 2010, Developmental and comparative immunology.

Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells

A. de Bruin, Z. Sebestyén, J. Kuball, 2019, Journal of Immunotherapy for Cancer.

The Role of γδ T Cells as a Line of Defense in Viral Infections after Allogeneic Stem Cell Transplantation: Opportunities and Challenges

L. Schrier, A. Bruns, Z. Sebestyén, 2022, Viruses.

αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies.

R. Raymakers, M. Minnema, J. Boelens, 2021, Blood advances.

Hunting for clinical translation with innate-like immune cells and their receptors

W. Scheper, Z. Sebestyén, J. Kuball, 2014, Leukemia.

Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

N. Taylor, J. Verweij, A. Sewell, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Identification of a tumor-specific allo-HLA-restricted γδTCR.

A. Heck, M. Nishimura, J. Falkenburg, 2019, Blood advances.

GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR

H. Vié, R. Raymakers, Z. Sebestyén, 2018, Front. Immunol..

Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model

Jacqueline Alblas, C. Robin, J. Alblas, 2018, Oncoimmunology.

T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.

R. Debets, D. Schipper, C. Berrevoets, 2012, Human gene therapy.

Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge

C. Britten, J. Kuball, T. Straetemans, 2015, Cancer Immunology, Immunotherapy.

Strategies to improve γδTCRs engineered T-cell therapies for the treatment of solid malignancies

Z. Sebestyén, J. Kuball, D. Beringer, 2023, Frontiers in Immunology.

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds

Z. Sebestyén, S. Heijhuurs, J. Kuball, 2021, Journal for ImmunoTherapy of Cancer.

TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product.

M. Simonis, Judith G. M. Bergboer, Z. Sebestyén, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Enhancing cancer targeting of γ9δ2TCR through modified NKG2D co-stimulation

Z. Sebestyén, J. Kuball, S. Heijhuurs, 2021, bioRxiv.

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit

B. Nuijen, Z. Sebestyén, J. Kuball, 2023, Immuno-oncology technology.